199 related articles for article (PubMed ID: 31088547)
1. Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
Visser S; Hou J; Bezemer K; de Vogel LL; Hegmans JPJJ; Stricker BH; Philipsen S; Aerts JGJV
BMC Cancer; 2019 May; 19(1):440. PubMed ID: 31088547
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
[TBL] [Abstract][Full Text] [Related]
4. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Fiala O; Pesek M; Skrickova J; Kolek V; Salajka F; Tomiskova M; Satankova M; Kultan J; Kuliskova J; Svaton M; Hrnciarik M; Hejduk K; Chloupkova R; Topolcan O; Hornychova H; Nova M; Ryska A; Finek J
Tumour Biol; 2017 Feb; 39(2):1010428317691186. PubMed ID: 28218046
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
Park S; Kim HJ; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Choi SH; Rho JK; Lee JC
BMC Cancer; 2016 Jul; 16():417. PubMed ID: 27388008
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M
Invest New Drugs; 2016 Oct; 34(5):625-35. PubMed ID: 27350064
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
[TBL] [Abstract][Full Text] [Related]
9. Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
Agulló-Ortuño MT; García-Ruiz I; Díaz-García CV; Enguita AB; Pardo-Marqués V; Prieto-García E; Ponce S; Iglesias L; Zugazagoitia J; López-Martín JA; Paz-Ares L; Nuñez JA
Cancer Chemother Pharmacol; 2020 Mar; 85(3):525-535. PubMed ID: 31832811
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer.
Yoon JY; Park CK; Choi YD; Oh IJ; Kim YC
Thorac Cancer; 2019 Apr; 10(4):942-949. PubMed ID: 30864258
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
13. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
14. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
15. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
17. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
18. Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Zhao XM; Zhao J; Wu XH; Luo ZG; Wang HJ; Yu H; Chang JH; Wang JL
Cancer Chemother Pharmacol; 2017 Oct; 80(4):851-860. PubMed ID: 28755014
[TBL] [Abstract][Full Text] [Related]
19. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
